We are live on ! Find out more
ZBIO

ProShares UltraPro Short NASDAQ Biotechnology
ZBIO

Delisted

ZBIO was delisted on the 27th of March, 2020.

Back to rankings

4 hedge funds and large institutions have $1.07M invested in ProShares UltraPro Short NASDAQ Biotechnology in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more capital invested

Capital invested by funds: $1.06M → $1.07M (+$17K)

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

99% less call options, than puts

Call options by funds: $2K | Put options by funds: $258K

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
2
Calls
$2K
Puts
$258K
Net Calls
-$256K
Net Calls Change
-$256K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$436K
2
Morgan Stanley
Morgan Stanley
New York
+$121K
3
UBS Group
UBS Group
Switzerland
+$60.2K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$471K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$360K
3
VF
Virtu Financial
New York
-$243K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$519K +$436K +23,731 New
VF
2
Virtu Financial
New York
$339K -$243K -13,202 -46%
Morgan Stanley
3
Morgan Stanley
New York
$145K +$121K +6,578 +82,225%
UBS Group
4
UBS Group
Switzerland
$72K +$60.2K +3,273 New
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
– -$360K -27,954 Closed
Jane Street
6
Jane Street
New York
– -$471K -25,591 Closed

ZBIO Hedge Fund Activity: Q4 2018 in Review

4 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q4 2018, worth a combined $1.07M — up 1.6% from $1.06M a quarter earlier.

Fund positioning in ZBIO was balanced in Q4 2018: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $436K. The largest seller was Jane Street, exiting entirely with an estimated $471K sold.

  • 4 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q4 2018, unchanged from Q3 2018.
  • Funds reported $1.07M of ProShares UltraPro Short NASDAQ Biotechnology stock for Q4 2018, up 1.6% quarter-over-quarter.
  • 2 funds opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q4 2018 and 2 closed out, a net change of 0 holders.
  • The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q4 2018 was Citadel Advisors, an estimated $436K added.
  • The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q4 2018 was Jane Street, an estimated $471K sold.

Based on aggregated 13F filings for Q4 2018.